Focus Partners Advisor Solutions’s Regeneron Pharmaceuticals REGN Stock Holding History

Focus Partners Advisor Solutions’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.35M	Sell	2,165 -3,125	-59%	-$2.13M	0.01%	472
2026 Q1	$4.09M	Buy	5,290 +887	+20%	+$679K	0.04%	201
2025 Q4	$3.4M	Buy	4,403 +1,494	+51%	+$1.01M	0.04%	211
2025 Q3	$1.8M	Buy	+2,909	New	+$1.64M	0.02%	365
2025 Q2	–	Sell	-849	Closed	-$538K	–	1156
2025 Q1	$538K	Buy	+849	New	+$584K	0.01%	568
2024 Q4	–	Sell	-371	Closed	-$390K	–	853
2024 Q3	$390K	Buy	371 +3	+0.8%	+$3.34K	0.01%	502
2024 Q2	$387K	Buy	368 +158	+75%	+$153K	0.01%	432
2024 Q1	$202K	Buy	+210	New	+$200K	0.01%	583
2022 Q4	–	Sell	-451	Closed	-$311K	–	412
2022 Q3	$311K	Buy	+451	New	+$284K	0.02%	299
2022 Q1	–	Sell	-342	Closed	-$216K	–	348
2021 Q4	$216K	Buy	+342	New	+$210K	0.05%	130

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Focus Partners Advisor Solutions's REGN Position: Q2 2026 in Review

Focus Partners Advisor Solutions reduced its Regeneron Pharmaceuticals (REGN) stake by 59% in Q2 2026, selling an estimated $2.13M and leaving 2,165 shares worth $1.35M. The position accounts for 0.01% of the portfolio, ranked #472.

Focus Partners Advisor Solutions first reported a position in REGN in Q4 2021 and has held it in 10 quarters since. The position peaked at $4.09M in Q1 2026. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Focus Partners Advisor Solutions held 2,165 shares of Regeneron Pharmaceuticals worth $1.35M as of Q2 2026.
Focus Partners Advisor Solutions sold 3,125 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $2.13M.
Regeneron Pharmaceuticals made up 0.01% of Focus Partners Advisor Solutions's portfolio in Q2 2026, its #472 holding.
Focus Partners Advisor Solutions first reported a position in Regeneron Pharmaceuticals in Q4 2021 and has held it in 10 quarters since.
Focus Partners Advisor Solutions's Regeneron Pharmaceuticals position peaked at $4.09M in Q1 2026.
1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Focus Partners Advisor Solutions's 13F filing for Q2 2026, filed 6 Aug 2026.